Extract from Baillie
Rhinomed is undervalued on our numbers, with a base case valuation
of $0.13 per share and optimistic case of $0.44 on a probability-weighted
DCF valuation. Our target price sits near our base case.
They have to be joking. They cannot even get the current sp correct. It closed at 2.6c on Nov 17th not 3cents as published.
Go for it guys buy up big. Maybe brokers want to offload?
Broker Valuations, page-5
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)